ACTION
Disease site: Breast Cancer
Treatment Modality: Chemotherapy
Status: Closed to recruitment
This trial will address the following hypotheses:
(1) that adjuvant chemotherapy (either AC or EC) will increase the relapse free survival interval in older women with high risk breast cancer, and
(2) that two weekly (accelerated) therapy with GCSF support will not cause undue toxicity in this patient group, compared to the standard three weekly and that both chemotherapy regimens will be acceptable and tolerated in this group of patients
ACTION will randomise approximately 1000 patients in the UK. It is open to all centres and no restrictions on the number or size of centres is envisaged.
Sub-studies include a Quality of Life Study and Biological Marker Study.
The ACTION Trial is co-ordinated by the ICR - Clinical Trials & Statistics Unit and is supported by the NCRI Breast Clinical Studies Group.
Chief Investigator: | Professor Robert Leonard, Charing Cross Hospital, London |
Sponsor: | Institute of Cancer Research and Imperial College Healthcare NHS Trust |
Source of funding: | Cancer Research UK, AMGEN |
In the Clinical Trials Section
